Data on Cancer Discussed by Researchers at Complutense University of Madrid (Bicalutamide Enhances Conventional Chemotherapy in In Vitro and In Vivo Assays Using Human and Canine Inflammatory Mammary Cancer Cell Lines).

Researchers at Complutense University of Madrid have conducted a study on the use of bicalutamide, a non-steroidal anti-androgen, in combination with doxorubicin and docetaxel chemotherapy for the treatment of inflammatory breast cancer (IBC) and inflammatory mammary cancer (IMC) in humans and canines. The study found that bicalutamide enhanced the effectiveness of chemotherapy in reducing cell viability, migration, and tumor growth in both cell lines. Additionally, the combination treatment increased intratumoral testosterone levels, which have been associated with reduced tumor progression. The researchers suggest that the addition of bicalutamide to chemotherapy may be a potential treatment option for IBC and IMC. [Extracted from the article]